Slide 1: Interim report Q1 2012/13
Interim report Q1 2012/13 By CEO Lars Marcher and CFO Michael Højgaard
Slide 2: Agenda
Agenda • Developments in Q1 2012/13 • Status of the GPS Four strategy • Outlook for 2012/13
Slide 3: Highlights for Q1 2012/13
Highlights for Q1 2012/13 • Solid start to FY 2012/13 • Conclusion of conditional agreement concerning acquisition of King Systems Inc. – important milestone 15% increase in • Revenue growth of 15% and organic growth of revenue 8% • Products launched after 1 October 2009 accounted for 11% of revenue
Slide 4: Highlights for Q1 2012/13
Highlights for Q1 2012/13 Revenue, DKKm EBIT before special items, DKKm EBIT margin, % 300 50 20 250 40 15 200 30 150 10 20 100 10 5 50 0 0 0 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 11/12 11/12 11/12 11/12 12/13 Q1 Q2 Q3 Q4 Q1 11/12 11/12 11/12 11/12 12/13 11/12 11/12 11/12 11/12 12/13 • Revenue of DKK 268.8m
Slide 5: Development in revenue for the quarter, regions
Development in revenue for the quarter, regions USA, DKKm Europe, DKKm Rest of the world, DKKm 100 180 50 80 150 40 60 120 30 90 40 20 60 20 30 10 0 0 0 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 11/12 11/12 11/12 11/12 12/13 11/12 11/12 11/12 11/12 12/13 11/12 11/12 11/12 11/12 12/13 • Revenue gr
Slide 6: Development in revenue for the quarter by business area
Development in revenue for the quarter by business area Anaesthesia, DKKm Patient Monitoring & Diagnostics, DKKm Emergency Care, DKKm 120 160 50 100 40 120 80 30 60 80 20 40 40 20 10 0 0 0 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 11/12 11/12 11/12 11/12 12/13 11/12 11/12 11/12 11/12 12/13 11/12
Slide 7: Improved cash flow
Improved cash flow DKKm Q1 2011/12 Q1 2012/13 Cash flow from operating activities -19.2 -6.3 Cash flow from investing activities, before acquisitions -8.8 -6.8 Free cash flow -28.0 -13.1 Cash flow from financing activities 35.3 22.9 • Cash flow from operating activities improved significantly in Q1
Slide 8: GPS Four: Status of Ambu's business strategy
GPS Four Status of Ambu's business strategy
Slide 9: GPS Four – overview
GPS Four — overview BUILDING A PLATFORM 2009/10 Establishment of sales regions Establishment of global innovation organisation Implementation of global IT systems Transfer of remaining Danish production to Asia commenced Expansion of factory in China COST OPTIMISATION 2010/11 + Transfer of productio
Slide 10: Strategic activities
Strategic activities GPS 1: Innovation • Satisfactory growth rates for aScope, SmartInfuser Pain Pump and other product launches • New products account for 11% of revenue in Q1 2012/13 • Further development of existing product portfolio and development of 'green' versions of products • Integration o
Slide 11: Agreement concerning acquisition of King Systems
Agreement concerning acquisition of King Systems • Perfectly in line with strategy First-class • King Systems' products very complementary of Ambu's products products • Increasing Ambu's volume and strengthening market position Strong • Equates to more than doubling of sales within Anaesthesia brand
Slide 12: Acquisition strengthens Ambu significantly
Acquisition strengthens Ambu significantly * As reported, Ambu FY 2011/12A ** Pro-forma data based on Ambu FY 2011/12A September and King Systems FY 2011/12A April
Slide 13: Outlook 2012/13
Outlook 2012/13
Slide 14: The outlook for 2012/13 is unchanged
The outlook for 2012/13 is unchanged 2012/13 Assumptions Revenue In the region of DKK 1,125m Increased revenue in emerging markets. Full-year effect of acquired electrode business and success with new products Growth in DKK and local Including full-year effect of acquired electrode currencies 7-8% b
Slide 15: Questions
Ambu* Ideas that work for life Questions
Slide 16: Read more at www.ambu.com
READ MORE AT WWW.AMBU.COM For further information, please contact: CEO Lars Marcher, lm@ambu.com or +45 5136 2490 CFO Michael Højgaard, miho@ambu.com or +45 4030 4349